Claim Amendments

Please amend the claims as shown below.

1. (currently amended) A crystalline solid famciclovir form I, characterized by a XRD pattern with peaks at 15.5 and 15.9 ± 0.2 deg. 2θ, wherein the crystalline solid famciclovir contains less than about 5% wt of another famciclovir crystalline form.
2. (original) The crystalline solid famciclovir of claim 1, further characterized by a XRD pattern with peaks at 8.2, 10.4, 14.5, 17.0, 17.7, 19.5, 20.6, 21.1, 22.3, 23.0, 23.9, 24.4, 25.6, 26.5, 28.6, 29.0 and 32.6 ± 0.2 deg. 2θ.
3. (original) The crystalline solid famciclovir of claim 2, further characterized by a XRD pattern as substantially depicted in Fig. 1.
4. (canceled)
5. (currently amended) The crystalline solid famciclovir of any one of claims 1-3, wherein the crystalline solid famciclovir contains less than about 5% wt of form II.
6. (currently amended) The crystalline solid famciclovir of claim 5 [[[4]]], wherein the crystalline solid famciclovir contains less than about 1% wt of ~~other~~ another famciclovir crystalline form ~~forms~~.
7. (original) The crystalline solid famciclovir of claim 6, wherein the crystalline solid famciclovir contains less than about 1% wt of form II.
8. (currently amended) A crystalline solid famciclovir form II, characterized by a XRD pattern with peaks at 16.2 and 16.4 ± 0.2 deg. 2θ, wherein the crystalline solid famciclovir contains less than about 5% wt of another famciclovir crystalline form.
9. (original) The crystalline solid famciclovir of claim 8, further characterized by a XRD pattern with peaks at 8.3, 14.6, 17.8, 19.7, 20.7, 21.2, 24.5 and 25.6 ± 0.2 deg. 2θ.
10. (original) The crystalline solid famciclovir of claim 9, further characterized by a XRD pattern as substantially depicted in Fig. 2.
11. (currently amended) A crystalline solid famciclovir solvate ~~form III~~, characterized by a XRD pattern with peaks at 6.6 and 13.0 ± 0.2 deg. 2θ.
12. (currently amended) The crystalline solid famciclovir solvate of claim 11, further characterized by a XRD pattern with peaks at 15.9, 16.7, 18.4, 19.6, 24.5, 25.0 and 26.2 ± 0.2 deg. 2θ.

13. (currently amended) The crystalline solid famciclovir solvate of claim 12, further characterized by a XRD pattern as substantially depicted in Fig. 3.

14. (currently amended) The crystalline solid famciclovir solvate of claim 11, wherein the crystalline solid ~~of~~ famciclovir solvate is a methanol solvate.

15. (currently amended) The crystalline solid famciclovir solvate of claim 11, wherein the crystalline solid ~~of~~ famciclovir solvate is an ethanol solvate.

16. (original) Crystalline solid famciclovir methanol solvate.

17. (original) Crystalline solid famciclovir ethanol solvate.

18. (original) A process for preparing the crystalline solid famciclovir of claim 1, comprising the steps of:

a) triturating an anhydrous famciclovir form in an organic solvent selected from the group consisting of isopropyl alcohol, acetonitrile, and diethylether; and

b) isolating the crystalline solid famciclovir of claim 1.

19. (original) A crystalline solid famciclovir form I prepared by triturating an anhydrous famciclovir form in an organic solvent selected from the group consisting of isopropyl alcohol, acetonitrile, and diethylether.

20. (original) A process for preparing the crystalline solid famciclovir of claim 1, comprising the steps of:

a) heating crystalline solid famciclovir of claim 11 to about 40^0C to about 90^0C; and

b) isolating the crystalline solid famciclovir of claim 1.

21. (original) The process of claim 20, wherein the heating of the crystalline solid famciclovir of claim 11 is performed at a temperature of about 60^0C to about 70^0C.

22. (original) A process for preparing the crystalline solid famciclovir of claim 1, comprising the steps of:

a) heating famciclovir monohydrate to about 40^0C to about 80^0C; and

b) isolating the crystalline solid famciclovir of form I.

23. (currently amended) The process of claim 22, wherein step a) is performed by heating a mixture of the famciclovir monohydrate and ~~includes the~~ crystalline solid famciclovir form I characterized by a XRD pattern with peaks at 15.5 and 15.9 ± 0.2 deg. 2θ ~~of claim 1~~.

24. (original) The process of claim 22, wherein the heating of famciclovir monohydrate is performed at a temperature of about 60^0C to about 70^0C.

25. (currently amended) A process for preparing the crystalline solid famciclovir of claim 1, comprising the steps of:

a) heating the crystalline solid famciclovir form II, characterized by a XRD pattern with peaks at 16.2 and 16.4 ± 0.2 deg. 2θ, ~~of claim 8~~ to about 40^0C to about 90^0C; and

b) isolating the crystalline solid famciclovir of claim 1.

26. (currently amended) The processes of any one of claims 18, 20, 22 and 25, wherein the isolated crystalline solid famciclovir ~~of claim 1~~ contain less than about 5% wt of other famciclovir crystalline forms.

27. (currently amended) The processes of any one of claims 18, 20, 22 and 25, wherein the isolated crystalline solid famciclovir ~~of claim 1~~ contains less than about 5% wt of crystalline famciclovir form II ~~the form of claim 8~~.

28. (currently amended) The process of claim 26, wherein the isolated crystalline solid famciclovir ~~of claim 1~~ contain less than about 1% wt of other famciclovir crystalline forms.

29. (currently amended) The process of claim 28, wherein the isolated crystalline solid famciclovir ~~of claim 1~~ contains less than about 1% wt of crystalline famciclovir form II ~~the form of claim 8~~.

30. (currently amended) A process for preparing the crystalline solid famciclovir of claim 1, comprising the steps of:

a) providing a solution of famciclovir in an organic solvent selected from the group consisting of dichloromethane, chloroform, acetonitrile, ethylacetate, acetone, THF, diethyl ether/dichloromethane mixture, dichloromethane/toluene mixture, ethylacetate/toluene mixture, acetonitrile/toluene mixture[[[,]]] and dimethylacetamide ~~and isopropylalcohol~~,

b) cooling the solution, and

c) isolating the crystalline solid famciclovir of claim 1.

31. (currently amended) A process for preparing the crystalline solid famciclovir of claim 8, comprising the steps of:

a) providing a solution of famciclovir in ~~an organic solvent selected from the group consisting of~~ ethanol ~~and n-butanol~~,

b) cooling the solution whereby the crystalline solid famciclovir form II crystallizes, and

c) isolating the crystalline solid famciclovir of claim 8.

32. (currently amended) A process for preparing a mixture of crystalline solid famciclovir form II, characterized by a XRD pattern with peaks at 16.2 and 16.4 ± 0.2 deg. 2θ, ~~of claim 8~~ and crystalline solid famciclvir of claim 1, comprising the steps of:

a) providing a solution of famciclovir in an organic solvent selected from the group consisting of chloroform, ethylacetate, diethyl ether/dichloromethane mixture, tetrahydrofuran, acetonitrile/toluene mixture, dimethylacetamide and isopropanol,

b) cooling the solution, and

c) isolating the mixture of the crystalline solid famciclovir form II, characterized by a XRD pattern with peaks at 16.2 and 16.4 ± 0.2 deg. 2θ, ~~of claim 8~~ and the crystalline solid famciclovir of claim 1.

33. (original) A process for preparing the crystalline solid famciclovir of claim 11, comprising the steps of:

a) triturating an anhydrous famciclovir in methanol; and

b) isolating the crystalline solid famciclovir of claim 11.

34. (original) A process of preparing a mixture of the crystalline solid famciclovir of claim 11 and the crystalline solid famciclovir of claim 1, comprising the steps of:

a) triturating an anhydrous famciclovir in ethanol; and

b) isolating the mixture of the crystalline solid famciclovir of claim 11 and the crystalline solid famciclovir of claim 1.

35. (currently amended) A process of preparing a crystalline solid famciclovir monohydrate ~~monhydrate~~, comprising the steps of:

a) providing a solution of famciclovir in an organic solvent selected from the group consisting of acetonitrile, ethyl acetate, acetone, isopropyl alcohol, tetrahydrofuran, ethanol/water mixture, ~~acetone/water mixture,~~ DMF/water mixture, DMA/water mixture, acetonitrile/water mixture, methanol/water mixture, tetrahydrofuran/water mixture, and isopropyl alcohol/water mixture; and

b) cooling the solution; and

c) isolating the crystalline solid famciclovir monohydrate.

36. (currently amended) A process for preparing a mixture of the crystalline solid famciclovir solvate of claim 11 and crystalline solid famciclovir monohydrate, comprising the steps of:

a) triturating anhydrous famciclovir in an organic solvent selected from the group consisting of isopropyl alcohol and ethanol; and

b) isolating the mixture of the crystalline solid famciclovir solvate of claim 11 and crystalline solid famciclovir monohydrate.

37. (currently amended) A solid pharmaceutical composition comprising the crystalline solid famciclovir of claim 1 and a pharmaceutically-acceptable excipient~~, wherein the crystalline solid famciclovir of claim 1 contains less than about 5% wt of other famciclovir crystalline forms~~.

38. (currently amended) The solid pharmaceutical composition of claim 37, wherein the crystalline solid famciclovir of claim 1 contains less than about 1% wt of ~~other~~ another famciclovir crystalline form ~~forms~~.

39. (currently amended) A solid pharmaceutical composition comprising the crystalline solid famciclovir of claim 8 and a pharmaceutically-acceptable excipient~~, wherein the crystalline solid famciclovir form II contains less than about 5% wt of other famciclovir crystalline forms~~.

40. (currently amended) The solid pharmaceutical composition of claim 39, wherein the crystalline solid famciclovir of claim 8 contains less than about 1% wt of ~~other~~ another famciclovir crystalline form ~~forms~~.

41. (currently amended) A solid pharmaceutical composition comprising a crystalline solid famciclovir solvate of claim 11 and a pharmaceutically-acceptable excipient, wherein the crystalline solid famciclovir solvate of claim 11 ~~form III~~ contains less than about 5% wt of another ~~other~~ famciclovir crystalline form ~~forms~~.

42. (currently amended) The solid pharmaceutical composition of claim 41, wherein the crystalline solid famciclovir of claim 11 contains less than about 1% wt of another ~~other~~ famciclovir crystalline form ~~forms~~.

43. (currently amended) A method of treating a human in need of treatment with famciclovir comprising administering to the human the pharmaceutical composition of any one of claims 37-42.